A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
Key Highlights
- ➤Intismeran plus KEYTRUDA cut melanoma recurrence or death risk 42% versus KEYTRUDA alone
- ➤Combination reduced distant metastasis or death risk 38% versus KEYTRUDA alone
- ➤Moderna shares fell 17.57% despite positive Phase 3 results
- ➤BioNTech terminated colorectal cancer Phase 2 monotherapy trial after overall-survival imbalance
- ➤MindWalk processed 890,634 antibody sequences in 4 hours and 41 minutes
Expert Statements
Dr. Dean Y. Li, President, Merck Research Laboratories
“INTerpath-001 is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy”
Stéphane Bancel, Chief Executive Officer, Moderna
“From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient’s tumor. The INTerpath-001 results mark a defining moment for that vision and show what’s possible when we rethink how medicines are made”
Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer, BioNTech
“While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments and will help inform the further development of investigational mRNA cancer immunotherapies”
Dr. Jennifer Bath, President and Chief Executive Officer, MindWalk
“Every antibody drug carries a question: will the patient’s own immune system attack it. Answering that question late is one of the most expensive failures in this industry.”
AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and Moderna announced detailed results from the Phase 3 INTerpath-001 trial showing that intismeran autogene, given with KEYTRUDA®, significantly reduced the risk of melanoma recurrence or death by 42% compared with KEYTRUDA alone. Moderna’s shares still fell 17.57% that day. Beneath the trading is a scientific result that matters for the whole field: a therapy built around immune targets selected from a patient’s own tumor can change outcomes. The open question now is how well, how fast and how cheaply those targets can be chosen. Companies mentioned in today’s commentary include: MindWalk Holdings Corp. (NASDAQ: HYFT), Moderna, Inc. (NASDAQ: MRNA), Merck & Co., Inc. (NYSE: MRK), BioNTech SE (NASDAQ: BNTX).
Get started
Create a free account to read the full story.